Company Overview and News

 
IG Petrochemicals eyes 2x turnover at Rs 2,000 cr by FY21

2018-08-26 moneycontrol
IG Petrochemicals (IGPL), which makes phthalic anhydride (PA) chemical aims to double turnover to Rs 2,000 crore by 2021 after completion of its brownfield expansion worth Rs 300 crore.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Record Date

2018-07-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Shareholders meeting

2018-07-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Corrigendum

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Shareholders meeting

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Shareholders meeting

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Updates

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Financial Result Updates

2018-07-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Appointment

2018-07-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Appointment

2018-07-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Thirumalai Chemicals Limited - Outcome of Board Meeting

2018-07-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
ICICI Pru, Asian Paints, Symphony results

2018-07-23 thehindubusinessline
Asian Paints, Borosil Glass, Century Plyboards, Chambal Fertilizers, Coromandel Engineering, Elantas Beck, Filatex, GG Dandekar, Glaxo Pharma, Hexaware, ICICI Pru Life, Info Edge, Inox Leisure, Insilco KRBL, KSB Pumps, Kalyani Steels, Kajaria Ceramics, Navin Fluorine, Network18, Rane Brake, Radico Khaitan, Symphony, Teamlease, Thirumalai Chemicals, TV18 Broadcast and Wendt (India) are among the 40 companies that will declare April-June quarter results on Tuesday.
500820 500249 532706 KAJARIACER INOXLEISUR 532548 532800 533167 NAUKRI ASIANPAINT 532777 COROENGG TIRUMALCHM 532497 CENTURYPLY RADICO 500233 500235 KSL KSBPUMPS 500412 TV18BRDCST

 
Thirumalai Chemicals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TIRUMALCHM 500412

 
Portfolio rejig: Exiting IG Petrochem Thirumalai as import protection may end

2018-07-13 moneycontrol
The growth outlook for phthalic anhydride (PA) chemicals is one such area which has caught our attention. While the PA domestic industry, dominated by IG Petrochem and Thirumalai Chemicals, is driven by robust end markets of poly vinyl chloride (PVC), resins and pigments, the possibility of higher inexpensive import of PA is a cause for concern. On account of this, we are exiting our portfolio exposure to IG Petrochem and Thirumalai Chemicals in our midcap and Diwali portfolio, respectively.
TIRUMALCHM 500412

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

6h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...